[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oxford University Clinical Research Unit, Vietnam\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100558494","phase-2-adaptive-dengue-antiviral-platform-trial-100558494",false,"NCT06551844","Adaptive Dengue Antiviral Platform Trial","Adaptive Dengue Antiviral Platform Trial (ADAPT): a Phase 2 Randomized, Adaptive, Open Label Trial for Antiviral Screening in Patients With Early Symptomatic Dengue","ADAPT","Inclusion Criteria:\n\n* Female or male patients with a clinical diagnosis of dengue virus infection and less than 48 hours of fever\n* Positive NS1 rapid diagnostic test\n* \\>= 10 years or ≥ 18 years of age (depending on license of therapeutic being evaluated)\n* Patient is able to give written informed consent or assent for full participation in the study.\n* Agreement to stay in hospital for duration of the intervention (most will be 5 days) and follow-up visits at day 30 and 60 post enrolment.\n\nExclusion Criteria:\n\n* Meets criteria for severe dengue at baseline (severe plasma leakage leading to dengue shock syndrome, fluid accumulation with respiratory distress, severe bleeding, severe organ involvement - AST\u002FALT\\>1000 U\u002FL, impaired consciousness, multiple organ dysfunction)\n* Pregnancy (either clinically confirmed or by urine dipstick for human chorionic gonadotrophin hormone)\n* Breastfeeding women\n* Localising features suggesting an alternative\u002Fadditional diagnosis, e.g. pneumonia, sepsis\n* Renal failure (baseline eGFR \\\u003C 30ml\u002Fmin)\n* History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic or immunosuppressive disorders\n* History of allergic disease, allergic reactions or known hypersensitivity to any component of the study product (Mild non-medication allergies allowed)\n* Any condition that, in the opinion of the investigator, would complicate or compromise the study or well-being of the participant\n* Participation or planned participation in a study involving the administration of an investigational compound within the past one month.","ALL","10 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection\n\n* Primary objectives:\n\n  * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection\n  * To assess the safety and tolerability of the experimental drug(s) in dengue patients\n* Secondary objective:\n\n  * To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters",[27,28],"Dengue","Antiviral Drugs","RECRUITING","2026-04-24",{"date":32,"type":33},"2026-04-30","ACTUAL",{"date":35,"type":33},"2026-04-20",{"date":37,"type":21},"2030-12-31",{"name":39,"class":40},"Oxford University Clinical Research Unit, Vietnam","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100634728","phase-3-therapeutics-for-moderate-and-severe-dengue-100634728","NCT07543458","Therapeutics for Moderate and Severe Dengue","A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)","DEN-HOST","Inclusion Criteria:\n\n* Age ≥5 years\n* Decision to hospitalise\n* Clinical diagnosis of dengue\n* Participants must also have at least one of the following:\n\n  1. Severe abdominal pain or tenderness\n  2. Vomiting more than 3 times in the past 24 hours\n  3. Pleural effusion or ascites on clinical or radiological examination\n  4. Absolute haematocrit \\>50%\n  5. 15% increase in haematocrit compared with a baseline sample (defined as the first sample taken during the current illness)\n  6. Absolute platelet count \\\u003C50 × 10⁹\u002FL\n  7. Absolute platelet count \\\u003C100 × 10⁹\u002FL AND a drop \\>50 × 10⁹\u002FL in the past 32 hours\n  8. ALT or AST \\>400 IU\u002FL\n  9. Pulse pressure \\\u003C20mmHg or hypotension for age AND at least one of: peripheral capillary refill time \\>2 seconds; urine output 0.5ml\u002Fkg\u002Fhr; cold\u002Fclammy peripheries; agitation or altered mental state\n  10. Bleeding leading to hypotension for age or requiring blood transfusion or medical intervention (e.g. surgery, endoscopy, or vasoactive drugs)\n  11. Symptomatic bleeding into a critical site (intracranial, intraspinal, intraocular with visual impairment, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome)\n  12. Requirement for organ support, including vasopressors or inotropes, assisted ventilation, dialysis or haemofiltration, or coma (unresponsive to pain without sedation) or requirement for intravenous antiseizure medications\n\nExclusion Criteria:\n\n* Patients on ≥ day 10 of illness or who are clinically improving in the opinion of the managing doctor (the 'recovery phase') will be excluded from recruitment. Other exclusion criteria are specific to individual treatment comparisons, and do not preclude randomisation to other arms of the study.\n* A participant may not enter a specific treatment comparison if that treatment is considered to be indicated or contraindicated by the responsible clinician.","5 Years",{"count":52,"type":21},8800,[54],"PHASE3","The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.",[27,57,58,59,60,61,62,63],"Severe Dengue","Mosquito-Borne Diseases","Vector Borne Diseases","Arbovirus Infections","Flavivirus Infections","RNA Virus Infections","Hemorrhagic Fever",[65,66,67],"dengue treatment","host-directed therapy","host-targeted therapeutics","NOT_YET_RECRUITING","2026-04-15",{"date":71,"type":33},"2026-04-21",{"date":73,"type":21},"2026-10-01",{"date":75,"type":21},"2031-07-31",{"name":39,"class":40},18,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100390007","generating-collective-solutions-to-reduce-unnecessary-antibiotic-use-in-vietnam-100390007","NCT04358289","Generating Collective Solutions to Reduce Unnecessary Antibiotic Use in Vietnam","For communities:\n\nInclusion criteria:\n\n* Commune officials consent to take part;\n* Have a commune population larger than 3000 individuals;\n* Have active Women's Union and Farmers' Union groups with a paid commune-level representative;\n* Commune health centre has a doctor;\n* Commune health centre has electronic database.\n\nExclusion criteria:\n\n* Urban areas with a low proportion of farmers or low utilisation of CHCs for primary healthcare.\n\nFor study participants:\n\nInclusion criteria:\n\n* Participant is willing and able to give informed consent for participation in the study;\n* Community members normally resident in the study commune (living in the study commune and resident for at least three months);\n\nExclusion criteria:\n\n* No one will be actively excluded from participating in this population-based study.\n\nFor Commune Health Centers:\n\nInclusion criteria:\n\n* Serve a commune population larger than 3000 individuals;\n* Have an average caseload of at least 10 consultations per facility per week for ARI verified by checking the database system of the provincial centre for disease control and prevention (CDC) where the implementation study is being conducted;\n* Health centre doctor is normally employed at the centre and has been there for at least three months.\n\nExclusion criteria:\n\n* Low antibiotic prescription rate for ARI of below 40%.\n\nFor Patient records:\n\nInclusion criteria:\n\n* All patients' anonymised records.\n\nExclusion criteria:\n\n* Don't have national health insurance\u002Fnot recorded.",true,{"count":86,"type":21},3315,[88],"NA","The study aims to develop community-based interventions targetting inappropriate antibiotic dispensing and use behaviours in rural Vietnam and has 3 research components.\n\nCommunity and primary healthcare interventions: The investigators will conduct a four-armed cluster randomised controlled trial. The first arm will be a control arm with no interventions. The second intervention arm will have a basic antimicrobial stewardship intervention, involving working with the Ministry of Health, Medical Services Administration to revise guidelines for antibiotic prescribing for acute respiratory infections (ARI) in primary care, and then training primary healthcare doctors in their use. The third intervention arm will have basic antimicrobial stewardship guidelines and training for primary healthcare doctors, plus educational materials for the community, disseminated through posters, leaflets and local media channels. The fourth intervention arm will use a participatory action research approach to engage primary healthcare doctors and communities, in addition to the basic guidelines and training materials. The participatory action research approach will train local facilitators to lead community and health-worker groups through a cycle of problem identification, strategy development, implementation and review, focusing on inappropriate human and small-scale agricultural use of antibiotics.\n\nHospital interventions: The investigators will work with Provincial and District Hospitals serving these communities to implement quality improvement cycles for antibiotic stewardship, also using a participatory action research approach. This will also follow a cycle of a cycle of problem identification, strategy development, implementation and review.",[91],"Antibiotic Use",[93,94,95],"AMR","primary health care","Antimicrobial resistance","2023-12-05",{"date":98,"type":33},"2023-12-06",{"date":100,"type":33},"2020-02-27",{"date":102,"type":21},"2026-09",{"name":39,"class":40},1,""]